Mn Services Vermogensbeheer B.V. Lowers Stock Holdings in Hologic, Inc. (NASDAQ:HOLX)

Mn Services Vermogensbeheer B.V. lowered its position in shares of Hologic, Inc. (NASDAQ:HOLX - Free Report) by 7.2% in the 1st quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 86,960 shares of the medical equipment provider's stock after selling 6,700 shares during the period. Mn Services Vermogensbeheer B.V.'s holdings in Hologic were worth $5,372,000 as of its most recent filing with the Securities & Exchange Commission.

Other institutional investors and hedge funds also recently made changes to their positions in the company. Venturi Wealth Management LLC increased its position in shares of Hologic by 156.3% during the fourth quarter. Venturi Wealth Management LLC now owns 428 shares of the medical equipment provider's stock valued at $31,000 after acquiring an additional 261 shares in the last quarter. EverSource Wealth Advisors LLC grew its position in Hologic by 79.8% in the 4th quarter. EverSource Wealth Advisors LLC now owns 586 shares of the medical equipment provider's stock worth $42,000 after purchasing an additional 260 shares during the period. Smartleaf Asset Management LLC grew its position in Hologic by 36.9% in the 4th quarter. Smartleaf Asset Management LLC now owns 590 shares of the medical equipment provider's stock worth $43,000 after purchasing an additional 159 shares during the period. Smithfield Trust Co grew its position in Hologic by 160.0% in the 4th quarter. Smithfield Trust Co now owns 650 shares of the medical equipment provider's stock worth $45,000 after purchasing an additional 400 shares during the period. Finally, Raiffeisen Bank International AG bought a new stake in Hologic in the 4th quarter worth approximately $49,000. Institutional investors own 94.73% of the company's stock.

Insider Transactions at Hologic

In other news, Director Martin D. Madaus bought 5,445 shares of Hologic stock in a transaction dated Wednesday, May 7th. The shares were purchased at an average cost of $55.24 per share, with a total value of $300,781.80. Following the completion of the acquisition, the director now owns 5,445 shares of the company's stock, valued at $300,781.80. This trade represents a ∞ increase in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. Insiders own 1.88% of the company's stock.

Hologic Stock Down 1.6%

HOLX opened at $64.14 on Wednesday. The company has a debt-to-equity ratio of 0.54, a quick ratio of 2.52 and a current ratio of 3.24. Hologic, Inc. has a fifty-two week low of $51.90 and a fifty-two week high of $84.67. The firm's fifty day moving average is $58.93 and its 200 day moving average is $64.65. The stock has a market cap of $14.29 billion, a price-to-earnings ratio of 27.06, a price-to-earnings-growth ratio of 2.39 and a beta of 0.55.

Hologic (NASDAQ:HOLX - Get Free Report) last released its earnings results on Thursday, May 1st. The medical equipment provider reported $1.03 earnings per share for the quarter, beating analysts' consensus estimates of $1.02 by $0.01. The company had revenue of $1.01 billion for the quarter, compared to analysts' expectations of $1 billion. Hologic had a net margin of 13.83% and a return on equity of 19.71%. Hologic's revenue for the quarter was down 1.2% on a year-over-year basis. During the same quarter in the previous year, the company earned $1.03 EPS. On average, sell-side analysts forecast that Hologic, Inc. will post 4.28 earnings per share for the current fiscal year.

Analyst Ratings Changes

HOLX has been the subject of a number of research analyst reports. Stephens cut their target price on shares of Hologic from $77.00 to $70.00 and set an "overweight" rating for the company in a research report on Tuesday, May 13th. Morgan Stanley cut their price objective on shares of Hologic from $77.00 to $65.00 and set an "equal weight" rating for the company in a research report on Monday, May 5th. Citigroup cut their price objective on shares of Hologic from $80.00 to $70.00 and set a "neutral" rating for the company in a research report on Tuesday, March 4th. Argus downgraded shares of Hologic from a "buy" rating to a "hold" rating in a research report on Monday, March 3rd. Finally, Needham & Company LLC reissued a "hold" rating on shares of Hologic in a research report on Tuesday, May 27th. Twelve equities research analysts have rated the stock with a hold rating, five have given a buy rating and one has assigned a strong buy rating to the company. According to data from MarketBeat.com, the company presently has a consensus rating of "Hold" and an average target price of $77.42.

Hologic Profile

Hologic, Inc develops, manufactures, and supplies diagnostics products, medical imaging systems, and surgical products for women's health through early detection and treatment. The company operates through four segments: Diagnostics, Breast Health, GYN Surgical, and Skeletal Health. It provides Aptima molecular diagnostic assays to detect the infectious microorganisms; Aptima viral load assays for Hepatitis B virus, Hepatitis C virus, human immunodeficiency virus, and human cytomegalo virus; Aptima bacterial vaginosis and candida vaginitis assays for the diagnosis of vaginitis; Aptima SARS-CoV-2 and Panther Fusion SARS-CoV-2 assays to detect SARS-CoV-2; ThinPrep System for cytology applications; and Rapid Fetal Fibronectin Test that assists physicians in assessing the risk of pre-term birth.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.